Overview
Rivaroxaban is a selective direct Factor Xa inhibitor developed as an oral anticoagulant to replace warfarin in many clinical scenarios. It was first approved by the FDA in 2011 and has since become a first-line therapy for venous thromboembolism (VTE) and stroke prevention in non-valvular atrial fibrillation (NVAF). Unlike traditional anticoagulants, rivaroxaban does not require routine blood monitoring, offering significant convenience for patients. Its mechanism involves binding directly to Factor Xa's active site, interrupting the coagulation cascade. The drug is marketed under the brand name Xarelto by Bayer and Janssen Pharmaceuticals.
Physical and Chemical Properties
Rivaroxaban is a crystalline powder with moderate solubility characteristics. Its molecular structure includes a morpholinone ring and chlorothiophene moiety, contributing to its selective binding affinity for Factor Xa. The compound exhibits stability under standard storage conditions but may degrade upon prolonged exposure to moisture or UV light. Chemically, it demonstrates weak basic properties (pKa ~4.5) and has a plasma protein binding rate of approximately 92-95%. The drug's bioavailability ranges from 60-80% when taken with food, owing to enhanced absorption in the gastrointestinal tract.
Main Applications
In clinical practice, rivaroxaban is primarily used for three indications: stroke prevention in NVAF (20mg once daily), treatment of acute DVT/PE (15mg twice daily for 3 weeks, then 20mg daily), and postoperative VTE prevention in orthopedic surgeries (10mg daily). Beyond these core uses, ongoing research explores its potential in secondary cardiovascular prevention and pediatric applications. Compared to warfarin, rivaroxaban shows comparable efficacy with lower intracranial bleeding risks but requires careful renal function assessment due to its partial renal excretion (66%).
Safety and Storage
As a potent anticoagulant, rivaroxaban carries a black box warning for spinal/epidural hematoma risk during neuraxial anesthesia and irreversible bleeding events. It is contraindicated in patients with CrCl <15 mL/min and requires dose adjustment (15mg daily) for CrCl 15-50 mL/min. Pharmaceutical storage mandates protection from humidity and temperatures exceeding 25°C. Bulk API should be handled in controlled environments with proper PPE due to potential respiratory sensitization. Shelf life typically ranges from 24-36 months when properly packaged with desiccants.
B2B Procurement Guide
Pharmaceutical manufacturers sourcing rivaroxaban API should prioritize suppliers with EDQM Certificates of Suitability (CEP) or FDA Drug Master Files. Key quality parameters include polymorphic form (Form I preferred), residual solvents (ICH Q3C compliance), and particle size distribution (affects bioavailability). Current market dynamics show increasing competition from Indian and Chinese API producers, with contract manufacturing prices ranging from $4,000-$7,000/kg for GMP-grade material. Due to patent expirations in major markets (2024 in US), buyers should verify intellectual property status when considering generic procurement.